eGenesis is a gene editing and genome engineering company committed to the development of safe and effective human transplantable organs, tissues and cells to address the global organ crisis.Leveraging our platform, we’ve been able to address previously unbeatable biological hurdles in the transplantation field.We use a wide range of gene editing tools to push the boundaries of science for the field of transplantation. We believe next-generation gene editing tools can address a fundamental and global need for access to a greater number of human-compatible organs.

Lyra Therapeutics is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose and throat diseases. The company’s proprietary technology platform, XTreo™, is designed to precisely and consistently deliver medicines directly to the affected tissue for sustained periods with a single administration. The company’s initial product candidates, LYR-210 and LYR-220, are bioresorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver up to six months of continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis (CRS) that affects ~13 million people in the United States. The company is advancing LYR-210 as a potential alternative to surgery in an ongoing Phase 2 clinical trial for CRS patients who have failed medical management.

Homology Medicines, Inc. is a genetic medicines company dedicated to transforming the lives of patients suffering from rare genetic diseases with significant unmet medical needs by curing the underlying cause of the disease. Homology’s proprietary platform is designed to utilize its human hematopoietic stem cell-derived adeno-associated virus vectors (AAVHSCs) to precisely and efficiently deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing modality across a broad range of genetic disorders. Homology has a management team with a successful track record of discovering, developing and commercializing therapeutics with a particular focus on rare diseases and a robust intellectual property portfolio with issued composition of matter patents in the United States for its suite of 15 AAVHSCs. Homology believes that its compelling preclinical data, scientific expertise, product development strategy, manufacturing capabilities and intellectual property position it as a leader in the development of genetic medicines.$165 million IPO March 2018Novartis strategic alliance November 2017$83 million Series B financing July 2017

Ocular Therapeutix is focused on the development and commercialization of bioresorbable hydrogel based products including sustained release drug delivery products for the treatment of diseases and conditions of the eye including post-surgical inflammation and pain, glaucoma, allergic conjunctivitis and wet AMD. Completed IPO in July 2014 with $75 million in gross proceeds. Bankers: Morgan Stanley, Cowen, RBC, Oppenheimer. Completed follow-on public financing in June 2015 with $100 million in gross proceeds. Bankers: Morgan Stanley, Cowen, RBC, Nomura, BTIG.Signed a collaboration with a large biopharmaceutical company with up to $300 million in development and commercial milestone payments. Completed follow-on public financing in January 2017 with $25 million in gross proceeds.

CFO of a commercial stage medical device company with advanced energy devices that improve precision, access and safety in minimally invasive surgical procedures in Gynecology and ENT. The OmniGuide system includes a laser, a flexible fiber that delivers laser energy to the surgical site and customized handpieces that facilitate use in robotic and laparoscopic procedures.Experience: Helped grow the business and achieve status as # 130 on the Deloitte 500 fastest growing venture-backed companiesClosed $50 million in debt and equity financing

CFO of a publicly-traded commercial stage medical device company in the neurodiagnostics business.

CFO of a privately held commercial stage Clinical Research Organization (CRO) focused on medical imaging services for clinical studies being conducted by pharmaceutical and biotechnology companies. Company was purchased by a private equity firmOffices in the US, Germany, France and Denmark.

CFO during the early commercial phase of a venture-backed healthcare information technology company. Company was purchased by HCA. Raised $43 million in a venture capital financing with New Enterprise Associates, Whitney, Fraizer, Pacific Growth, 3COM and others.Closed a $9mm financing line with a commercial bank, including an equipment financing line and a working capital line Participated on a team that negotiated business development deals with Cerner and IBM

CFO of a biotechnology and medical device company focused on surgical sealants and adhesion barriersCompleted IPO in 1997 with Lehman, Piper Jaffray and Pacific Growth Equities. Company was purchased by Genzyme. Completed 3 rounds of venture capital financing totaling $45 million with Mayfield Fund, Kleiner Perkins, Domain, GE Pension Fund, H&Q, Patricof and others.

Senior financial position reporting to the CEOClinical stage biotechnology company developing therapies for the treatment of neurological diseases and pain management Company merged with StemCellsCompleted IPO in 1992 with Robertson Stephens and OppenheimerClosed two venture capital financing rounds totaling $26 million with JP Morgan, Genentech, Mayfield Fund, St Paul Capital, BancBoston

Publicly traded biotechnology company focused on the development of therapeutics and diagnostics for animal healthSenior financial position responsible for finance, treasury, SEC reporting

$1 billion defense electronics and computer graphics business acquired by Lockheed in 1986M&A Analyst evaluating acquisition targets in defense electronics and computer graphics.

Public accounting firm, one of the predecessor firms to PWCSenior Auditor responsible for overseeing audits of emerging growth technology and healthcare companies, commercial banks and other clientsWorked on several IPOsReceived CPA designation in 1983

Sales representative covering the Connecticut territory for a distributor of medical products including the NeoMed electrosurgical generator and the Laerdal line of CPR training equipmentResigned to pursue MBA full time in Sept 1979